A randomized phase III trial of stereotactic ablative radiotherapy for patients with up to 10 oligometastases and a synchronous primary tumor (SABR-SYNC): study protocol

Table 3 Follow-up schema

	Randomization	Last week of treatment	6 weeks	3, 6, 12, 18, 24 months	36, 48, 60 months
Clinic visit, including documentation of initiation of new cancer treatments	X^a	X	X	X	X^b
Imaging	X^c			X^d	X^d
Toxicity scoring (CTCAE version 5)		X	X	X	X^e
QOL scoring (FACT-G and EQ-5D-5L)	X			X

CTCAE Common Terminology Criteria for Adverse Events, FACT-G Functional Assessment of Cancer Therapy, General, EQ-5D-5L EuroQol 5-Dimension 5-Level
^aIncluding medical history and physical examination
^bVital status update and initiation of new cancer related treatment only
^cImaging to be completed within 12 weeks of randomization, per Pre-Treatment Evaluation Section
^dImaging as per site standard of care, and after progression at discretion of treating oncologist
^enew grade 2–5 toxicities if related to treatment

ISSN: 1472-684X